Business
World Mental Health Day & Q4 Conference Schedule
TheraCryf PLC announced its participation in several industry and investor conferences during Q4 2025, including BioSeed North on October 21 in Manchester, BioEurope from November 3-5 in Vienna, the ShareSoc Growth Company Seminar on November 13, Mello London on November 18-19, and London Life Sciences Week & Jefferies Global Healthcare Conference from November 17-21 in London. This announcement coincides with World Mental Health Day, highlighting the company's focus on developing treatments for mental disorders, particularly through its Ox-1 programme targeting binge eating and substance use disorders, impacting over 1 billion people globally. The company anticipates clinical trials for its orexin-1 blocker within a year. Disclaimer*
About this update from Theracryf Plc
TheraCryf plc ("TheraCryf", the "Company" or the "Group") Marking World Mental Health Day and Q4 Conference Schedule Update Alderley Park, 10 October 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, notes that today is World Mental Health Day and also shares its conference schedule for Q4 2025. World Mental Health Day 10 October is World Mental Health Day , aiming to raise awareness of mental health issues around the world and to mobilize efforts in support of mental health. Globally, more than 1 billion people live with a mental health condition*, with anxiety and depression being the most common, according to the World Health Organization. TheraCryf is honoured to be contributing to the potential treatment of mental disorders such as anxiety and addictive behaviour through its lead Ox-1 programme, a class-leading orexin-1 antagonist, targeting binge eating disorder and other substance use disorders. TheraCryf's Chief Operating Officer, Dr Helen Kuhlman, discusses the potential of orexin-based treatments for addictive behaviours in her article 'The Promise of Orexin-1 Antagonists in Addiction Treatment' , in the most recent edition of European Biopharmaceutical Review . *World Mental Health Today Report, September 2025 Q4 Conference Schedule The TheraCryf leadership team will also be attending the following industry and investor conferences and events during Q4. BioSeed North , 21 October 2025, Manchester BioEurope , 3-5 November 2025, Vienna ShareSoc Growth Company Seminar , 13 November 2025, London Mello London , 18-19 November 2025, London London Life Sciences Week & Jefferies Global Healthcare Conference , 17-21 November 2025, London Dr Huw Jones, CEO of TheraCryf, said: " As we mark World Mental Health Day, we are very much aware of the impact mental health conditions have on quality of life for sufferers and their families. We are on track with our work to enable our orexin-1 blocker to be used in clinical trials in under a year from now. The promise of these potential medicines is made very clear in the recent European Biopharma Review article and we look forward to reminding the industry and investors of the opportunity and plans for our lead programme during the upcoming conference season." -Ends- Enquiries TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO +44 (0)1625 315 090 [email protected] Singer Capital Markets (NOMAD & Joint Broker) Phil Davies / Oliver Platts / Patrick Weaver +44 (0)20 7496 3000 Turner Pope Investments (Joint Broker) James Pope / Andy Thacker +44 (0)20 3657 0050 Vigo Consulting Rozi Morris/ Melanie Toyne Sewell +44 (0)20 7390 0230 [email protected] About TheraCryf plc TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders [*orphan indication]. The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know-how for programmes from companies such as Shire (now Takeda). TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan. The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.